Xcout Intel
Kyntra Bio, Inc.
Kyntra Bio, Inc. is a biopharmaceutical enterprise focused on the entire spectrum of therapeutic innovation, from discovering new compounds to developing and commercializing them. Leveraging profound insights into hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology, the company strives to engineer effective medicinal solutions for anemia, fibrotic conditions, and various forms of cancer. Founded by Thomas B. Neff on September 29, 1993, Kyntra Bio, Inc. maintains its corporate headquarters in San Francisco, California.
Subscribe to see Kyntra Bio, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Kyntra Bio, Inc. at a glance
Kyntra Bio, Inc. is a biotech company headquartered in United States. It is publicly listed (0IL8) with a market capitalisation of $31.1M. Xcout tracks 16 named people at Kyntra Bio, Inc., including Thane Wettig (Chief Executive Officer & Director).
Kyntra Bio, Inc. leadership
- Thane WettigChief Executive Officer & Director
- David DeLuciaSenior Vice President & Chief Financial Officer
- Michelle SimonettiHead of People and Culture & Executive Director
- Gaia Vasiliver-ShamisDirector of IR & Communications - LifeSci Advisors
- John AldenCorporate Secretary & General Counsel
- Aoife BrennanDirector
10 more named people on record for Kyntra Bio, Inc., with roles, board committees and tenure — see the full roster →
Kyntra Bio, Inc. competitors
A few of Kyntra Bio, Inc.'s closest competitors — see the full list of competitors and alternatives →
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Xaira Therapeutics is an integrated biotechnology company headquartered in the San Francisco Bay Area in California. The company focuses on leveraging advanced scientific methods for therapeutic discovery and development.
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
Kortuc Inc. develops cancer radiotherapy solutions, specifically offering an innovative radiosensitizer designed to eliminate tumor hypoxia and maximize the effectiveness of radiation treatment. The company serves the medical and oncology research sectors by advancing clinical trials and expanding treatment options for cancer patients.
Endeavor BioMedicines, Inc. is a San Diego-based biotechnology company focused on developing novel treatments for conditions such as fibrosis.
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
Get Kyntra Bio, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Kyntra Bio, Inc. in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access